Please login to the form below

Not currently logged in
Email:
Password:

Xarelto uses extended in US

New FDA approval could be huge sales boost for Bayer's and J&J's anticoagulant

Bayer J&J Xarelto rivaoxaban

The US FDA has approved new uses for Bayer's and Johnson & Johnson's anticoagulant Xarelto that could expand the market for the drug by up to $1bn.

The agency gave the nod for Xarelto (rivaroxaban) to be used in the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), as well as to reduce the risk of recurrent DVT and PE following initial treatment.

The oral Factor Xa inhibitor is already FDA-approved to reduce the risk of DVT and PE after knee or hip replacement surgery and to reduce the risk of stroke in people with non-valvular atrial fibrillation (AF), and J&J said the new indication gives Xarelto the "broadest indication profile of any of the newer oral anticoagulants".

"Xarelto is the first oral anticlotting drug approved to treat and reduce the recurrence of blood clots since the approval of warfarin nearly 60 years ago," said Richard Pazdur, director of the Office of Haematology and Oncology Products in the FDA's Center for Drug Evaluation and Research (CDER).

The approval goes some way towards alleviating Bayer and J&J's disappointment back in June when Xarelto was turned down by the FDA as a treatment for patients with acute coronary syndrome (ACS), with the agency asking for more data.

The latest approval for Xarelto was granted on the back of three clinical trials which found the drug was as effective in DVT and PE as a combination of Sanofi's Lovenox (warfarin) and a vitamin K antagonist (VKA), and significantly more effective than placebo.

Around 2.1 per cent of patients treated with Xarelto experienced a recurrent DVT or PE in the studies, compared with 1.8-3 per cent of patients treated with the enoxaparin/VKA combination.

DVT and PE affect an estimated 300,000 to 1,600,000 patients each year in the US, killing between 60,000 and 100,000 people, and represent a sizeable new market for Xarelto. 

Bayer recorded Xarelto sales of €191m in the first nine months of 2012, up from €55m in the same period of 2011, and has said it expects the drug to achieve upwards of €2bn at peak.

6th November 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics